Skip to main content

Table 2 Outcome measures for matched groups 1 year following date of first ICS prescription

From: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands

Outcome

Extrafine-particle ICSa (n = 1399)

Fine-particle ICSb (n = 1399)

p-value

Asthma control

   

Risk-domain asthma control, n (%)

1236 (88)

1129 (81)

<0.001

Overall asthma control, n (%)

1091 (78)

934 (67)

<0.001

Severe exacerbations, n (%)

   

  0, n (%)

1236 (88)

1129 (81)

<0.001

  1, n (%)

108 (8)

184 (13)

  2+, n (%)

55 (4)

86 (6)

Treatment stability, n (%)

809 (58)

560 (40)

<0.001

Prescribed average daily dose of SABA, μg/d, n (%)

   

  0 μg/d, n (%)

686 (49)

461 (33)

<0.001

  1–100 μg/d, n (%)

326 (23)

343 (25)

  101 μg/d+, n (%)

387 (28)

595 (43)

1+ prescriptions of antifungal for candidiasis, n (%)

48 (3)

45 (3)

0.753

1+ asthma-related hospital admissions, n (%)

19 (1)

16 (1)

0.613

Respiratory medications in outcome period

   

Courses of acute oral corticosteroids, n (%)

   

  0, n (%)

1246 (89)

1135 (81)

<0.001

  1, n (%)

102 (7)

182 (13)

  2+, n (%)

51 (5)

82 (6)

SABA prescriptions, n (%)

   

  0, n (%)

686 (49)

461 (33)

<0.001

  1, n (%)

245 (18)

235 (17)

  2, n (%)

180 (13)

218 (16)

  3+, n (%)

288 (21)

485 (35)

ICS prescriptions (including initial prescription)

   

  2, n (%)

0 (0)

0 (0)

0.022

  3, n (%)

462 (33)

520 (37)

  4+, n (%)

937 (67)

879 (63)

Average ICS daily dose (μg/d, fluticasone-equivalentsc)

   

  0–150 μg/d, n (%)

460 (33)

263 (19)

<0.001

  151–250 μg/d, n (%)

484 (35)

416 (30)

  251–450 μg/d, n (%)

358 (26)

401 (29)

  451 μg/d+, n (%)

97 (7)

319 (23)

Average ICS daily dose (μg/d, EF-HFA-BDP/ciclesonide equivalent dosed), median (IQR)

185 (132–290)

272 (178–410)

<0.001

Average ICS daily dose (μg/d, EF-HFA-BDP/ciclesonide equivalent dosed)

   

  0–150 μg/d, n (%)

460 (33)

263 (19)

<0.001

  151–250 μg/d, n (%)

484 (35)

416 (30)

  251–450 μg/d, n (%)

358 (26)

401 (29)

  451 μg/d+, n (%)

97 (7)

319 (23)

LABA prescriptions in outcome period

770 (55)

875 (63)

<0.001

LTRA prescriptions in outcome period

83 (6)

47 (3)

0.001

  1. GERD gastro-oesophageal reflux disease, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LTRA leukotriene receptor antagonist, N/A not applicable, SABA short-acting β2-agonist
  2. a Extrafine-particle ICS: ciclesonide (Alvesco®); hydrofluoroalkane beclomethasone dipropionate (EF-HFA-BDP [Qvar®])
  3. b Fine-particle ICS: non-extrafine-particle beclomethasone dipropionate (Non-EF-BDP); fluticasone propionate (FP)
  4. c Fluticasone-equivalent dose for fine-particle ICS (FP and Non-EF-BDP) delivered via a pressurized-metered dose inhaler
  5. d EF-HFA-BDP/ciclesonide equivalent dose for extrafine-particle ICS delivered via a pressurized-metered dose inhaler
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us